CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

29 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

24 4月 2024 10:09:18 条件 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

16 4月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

16 4月 2024 06:59:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

01 3月 2024 07:00:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

27 2月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

18 12月 2023 16:53:03 条件 Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

14 12月 2023 16:30:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

08 11月 2023 07:00:03 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

03 11月 2023 12:01:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

30 10月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

06 9月 2023 08:00:00 条件 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

10 8月 2023 07:00:01 条件 Nasdaq GlobeNewswire

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

09 8月 2023 07:00:51 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

31 7月 2023 08:00:01 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

25 5月 2023 17:00:26 条件 Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

11 5月 2023 16:01:01 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

26 4月 2023 10:08:32 条件 Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

20 4月 2023 07:00:00 条件 Nasdaq GlobeNewswire